Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The BIM deletion polymorphism is a prognostic biomarker of EGFR-TKIs response in NSCLC: A systematic review and meta-analysis.

Oncotarget - 22 Sept 2015

Nie Wei, Tao Xia, Wei Hua, Chen Wan-sheng, Li Bing

Abstract excerpt

The prognostic value of Bcl-2-like protein 11 (BIM) deletion polymorphism for epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) treatment in non-small cell lung cancer (NSCLC) were reported. However, the results remained controversial. Thus, we did this systematic review and meta-analysis to address this issue. Databases including PubMed, Embase, and the Cochrane Register of Controlled...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Apoptosis Regulatory Proteins
Share to Bcl-2-Like Protein 11

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Carcinoma, Non-Small-Cell Lung

Share to Chi-Square Distribution

Share to Disease-Free Survival

Share to Molecular Targeted Therapy

Share to Protein Kinase Inhibitors

Share to Proto-Oncogene Proteins

Source

Open in PubMed Open full text

Identifiers

PMID: 26325082
DOI: 10.18632/oncotarget.4678
PMCID: PMC4694859

Genes

EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The BIM deletion polymorphism is a prognostic biomarker of EGFR-TKIs response in NSCLC: A systematic review and meta-analysis.PMID 26325082Read ↗

Prognostic Value of BIM Deletion in EGFR-Mutant NSCLC Patients Treated with EGFR-TKIs: A Meta-Analysis.Semantic proximity Read ↗

Role of BIM Deletion Polymorphism and BIM Expression as Predictive Biomarkers to Maximize the Benefit of EGFR-TKI Treatment in EGFR-Positive NSCLC.Semantic proximity Read ↗

BIM Gene Polymorphism Lowers the Efficacy of EGFR-TKIs in Advanced Nonsmall Cell Lung Cancer With Sensitive EGFR Mutations: A Systematic Review and Meta-Analysis.Semantic proximity Read ↗

Bcl-2-like protein 11 deletion polymorphism predicts survival in advanced non-small-cell lung cancer.Semantic proximity Read ↗

The Bim deletion polymorphism clinical profile and its relation with tyrosine kinase inhibitor resistance in Chinese patients with non-small cell lung cancer.Semantic proximity Read ↗

EGFR-TKIs plus chemotherapy demonstrated superior efficacy than EGFR-TKIs alone as first-line setting in advanced NSCLC patients with EGFR mutation and BIM deletion polymorphism.Semantic proximity Read ↗

A systematic review and meta-analysis of individual patient data on the impact of the BIM deletion polymorphism on treatment outcomes in epidermal growth factor receptor mutant lung cancer.Semantic proximity Read ↗

Clinical significance of BIM deletion polymorphism in non-small-cell lung cancer with epidermal growth factor receptor mutation.Semantic proximity Read ↗

Efficacy of EGFR tyrosine kinase inhibitors in patients having EGFR-activating mutations with or without BIM polymorphisms.Semantic proximity Read ↗

EGFR Inhibitors Plus Bevacizumab are Superior Than EGFR Inhibitors Alone as First-Line Setting in Advanced NSCLC With EGFR Mutations and BIM Deletion Polymorphisms (BIM-CLICaP).Semantic proximity Read ↗

Clinical Implications of the BIM Deletion Polymorphism in Advanced Lung Adenocarcinoma Treated With Gefitinib.Semantic proximity Read ↗

A common BIM deletion polymorphism mediates intrinsic resistance and inferior responses to tyrosine kinase inhibitors in cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.